BIOQUELL has won a prestigious award from the Department of Health and the NHS Purchasing and Supply Agency (PASA) in recognition of its hydrogen peroxide vapour (HPV) decontamination technology offering the greatest contribution in controlling Clostridium difficile.
The Department of Health and PASA launched the awards programme to highlight and celebrate innovation and success within the field of HCAI related technology and technological developments. They recognise that new and innovative technologies are helping to save lives and are making it easier for doctors and nurses to fight infection.
Upon receiving the award, Matt Parks, head of BIOQUELL's UK healthcare decontamination practice, said, "We are thrilled to have won such a prestigious award following many years of hard work carrying out painstaking ‘superbug’ eradication research in hospitals around the world. Winning this award highlights the importance of BIOQUELL’s presence within the NHS to help combat the threat posed by hospital acquired infection.”
BIOQUELL’s fully managed RBDS decontamination service was recently showcased in the HCAI technology innovation showcase programme as one of only six technologies trialled throughout seven UK hospitals. The trials proved that such a service can easily be implemented as part of a hospital's infection control regime offering quick turnaround times in the decontamination of infected areas.
The following is an extract from the NHS Purchasing and Supply Agency’s press release about the HCAI Technology Innovation Programme Awards:
'The award for innovative technological concept or new and novel product or technology offering the greatest contribution in controlling Clostridium difficile was won by BIOQUELL Plc for its hydrogen peroxide vapour system, which is highly effective in decontaminating enclosed rooms, wards and equipment. The process works by injecting hydrogen peroxide vapour into enclosed areas, which then condenses on the surfaces to kill a range of HCAIs, including MRSA and C. difficile.'
